High-throughput analysis of hematopoietic stem cell engraftment after intravenous and intracerebroventricular dosingRobert N. Plasschaert, Chris Mason, Luca Biasco et al.|Molecular Therapy|2022Cited by 13
Preclinical lentiviral hematopoietic stem cell gene therapy corrects Pompe disease-related muscle and neurological manifestationsJohn K. Yoon, Niek P. van Til, Jeffrey W. Schindler et al.|Molecular Therapy|2024Cited by 5
Genetically engineered microglia-like cells have therapeutic potential for neurodegenerative diseaseRobert N. Plasschaert, Chris Mason, Mark P. DeAndrade et al.|bioRxiv (Cold Spring Harbor Laboratory)|2021Cited by 2
Preclinical lentiviral vector-mediated hematopoietic stem and progenitor cell gene therapy corrects Pompe disease-related muscle and neurological manifestationsJohn K. Yoon, Niek P. van Til, Jeffrey W. Schindler et al.|bioRxiv (Cold Spring Harbor Laboratory)|2023Cited by 0
High-resolution cellular and molecular follow up of lysosomal disease patients treated with hematopoietic stem cell lentiviral gene therapyMariana Loperfido, Luca Biasco, Cristina Baricordi et al.|Molecular Genetics and Metabolism|2022Cited by 0